Global drugmakers find fault with quality of clinical trials conducted in Russia

Global drugmakers operating in Russia are unhappy with the current quality of clinical trials organized in Russia on the basis of local centers, according to recent statements of some representatives of the companies, reports The Pharma Letter’s local correspondent.

Producers say among the major weaknesses of such studies are poor experience of researchers, weak infrastructure, insufficient support of sponsors, undeveloped protocols and unwillingness to work with claims of partners.

This is despite the recent tightening of requirements for local research and clinical trials, which have been initiated by the Russian government with the aim of their better compliance with international standards.